S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
CGC   15.32 (+7.74%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
ACB   2.33 (+2.19%)
PRI   131.64 (+0.41%)
BAC   32.95 (-0.03%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
CGC   15.32 (+7.74%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
ACB   2.33 (+2.19%)
PRI   131.64 (+0.41%)
BAC   32.95 (-0.03%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
CGC   15.32 (+7.74%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
ACB   2.33 (+2.19%)
PRI   131.64 (+0.41%)
BAC   32.95 (-0.03%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
CGC   15.32 (+7.74%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
ACB   2.33 (+2.19%)
PRI   131.64 (+0.41%)
BAC   32.95 (-0.03%)
Log in

Regeneron Pharmaceuticals Price Target & Analyst Ratings (NASDAQ:REGN)

$344.48
+4.29 (+1.26 %)
(As of 11/19/2019 04:00 PM ET)
Today's Range
$340.22
Now: $344.48
$347.71
50-Day Range
$273.46
MA: $308.91
$348.48
52-Week Range
$271.37
Now: $344.48
$442.00
Volume63,787 shs
Average Volume816,717 shs
Market Capitalization$37.82 billion
P/E Ratio17.40
Dividend YieldN/A
Beta1.14

Analyst Ratings

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
20 Wall Street analysts have issued ratings and price targets for Regeneron Pharmaceuticals in the last 12 months. Their average twelve-month price target is $386.00, suggesting that the stock has a possible upside of 12.05%. The high price target for REGN is $453.00 and the low price target for REGN is $320.00. There are currently 11 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldHoldHold
Consensus Rating Score: 2.502.442.412.32
Ratings Breakdown: 0 Sell Rating(s)
11 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
12 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $386.00$385.38$393.33$393.06
Price Target Upside: 12.05% upside28.72% upside31.00% upside24.19% upside

Regeneron Pharmaceuticals (NASDAQ:REGN) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Regeneron Pharmaceuticals (NASDAQ:REGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2019SunTrust BanksInitiated CoverageHold$360.00Medium
11/11/2019Evercore ISIReiterated RatingBuy$395.00Low
11/6/2019Morgan StanleyBoost Price TargetEqual Weight$375.00 ➝ $387.00Low
11/6/2019CitigroupUpgradeNeutral ➝ Buy$340.00 ➝ $420.00Low
11/6/2019OppenheimerLower Price Target$480.00 ➝ $430.00Low
11/6/2019BMO Capital MarketsBoost Price TargetMarket Perform$344.00 ➝ $358.00Medium
11/6/2019JPMorgan Chase & Co.Reiterated RatingHold$375.00Medium
11/6/2019Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$310.00 ➝ $340.00Medium
10/16/2019Bank of AmericaInitiated CoverageNeutral$325.00Low
10/9/2019Canaccord GenuityLower Price TargetHold$353.00 ➝ $320.00Medium
10/8/2019CowenSet Price TargetHold$349.00Low
10/8/2019Piper Jaffray CompaniesSet Price TargetBuy$435.00Low
9/23/2019GuggenheimUpgradeNeutral ➝ Buy$355.00 ➝ $403.00Low
8/7/2019Robert W. BairdUpgradeNeutral ➝ Outperform$410.00Low
6/18/2019ArgusDowngradeBuy ➝ HoldHigh
6/11/2019Leerink SwannSet Price TargetBuy$453.00Low
5/13/2019Cantor FitzgeraldLower Price TargetNeutral$441.00 ➝ $405.00Medium
5/8/2019UBS GroupLower Price TargetBuy$480.00 ➝ $440.00Medium
4/17/2019Jefferies Financial GroupLower Price TargetHold$376.00 ➝ $343.00High
12/13/2018Goldman Sachs GroupUpgradeNeutral ➝ Conviction-BuyLow
8/6/2018BarclaysBoost Price TargetUnderweight ➝ Underweight$290.00 ➝ $305.00Low
5/7/2018Royal Bank of CanadaLower Price TargetSector Perform$342.00Low
4/9/2018Raymond JamesReiterated RatingOutperform ➝ Market PerformLow
3/13/2018BTIG ResearchReiterated RatingHoldMedium
3/13/2018Deutsche BankSet Price TargetHold$367.00Medium
(Data available from 11/19/2017 forward)
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel